NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$NNOX—The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit... Read more.
MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$MSFT—The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit... Read more.
Gay Qatari Refugee Returns to Face Qatar at the World Cup, Standing With Senator Scott Wiener to Say Love Is Not a Crime
Dr. Nasser Mohamed, the first openly gay Qatari to seek asylum, appears at San Francisco’s Qatar match alongside Senator Scott Wiener to declare that love is not... Read more.
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed... Read more.
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses,... Read more.
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #Bosulif–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along... Read more.
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
– frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade... Read more.
ComEd Continues Power Restoration Following Two Powerful Storms
Crews focus on remaining outages as weather clears across northern Illinois CHICAGO–(BUSINESS WIRE)–ComEd crews continue restoring power to customers... Read more.
Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–$NNOX #Health—Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased... Read more.
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
Did you buy WGS securities between April 16, 2025, and May 4, 2026? Affected WGS Investor Summary Who: GeneDx Holdings Corp. (NASDAQ: WGS) What: Securities fraud... Read more.